Evidence map›Paper›PMID 21385880›Full record

ArticleMolecular cancer research : MCR2011

Apoptosis is the essential target of selective pressure against p53, whereas loss of additional p53 functions facilitates carcinoma progression.

Xiangdong Lu, Chunyu Yang, Chaoying Yin, Terry Van Dyke, Karl Simin

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Xiangdong LuLineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina, USA.
Chunyu Yang
Chaoying Yin
Terry Van Dyke
Karl Simin
Frederick National Laboratory for Cancer Research · USUniversity of North Carolina at Chapel Hill · USNational Cancer Institute · US

Funding

SV40 T ANTIGEN MEDIATED ONCOGENESIS IN TRANSGENIC MICER01CA046283 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAN DYKE, TERRY A · 1988 to 2008
$3.1M
NCI NIH HHS 5-RO1CA46283NCI NIH HHS R01 CA046283
6 · The paper itself

Abstract

The high frequency of p53 mutation in human cancers indicates the important role of p53 in suppressing tumorigenesis. It is well established that the p53 regulates multiple, distinct cellular functions such as cell-cycle arrest and apoptosis. Despite intensive studies, little is known about which function is essential, or if multiple pathways are required, for p53-dependent tumor suppression in vivo. Using a mouse brain carcinoma model that shows high selective pressure for p53 inactivation, we found that even partially abolishing p53-dependent apoptosis by Bax inactivation was sufficient to significantly reduce the selective pressure for p53 loss. This finding is consistent with previous reports that apoptosis is the primary p53 function selected against during Eμ-myc-induced mouse lymphoma progression. However, unlike observed in the Eμ-myc-induced lymphoma model, attenuation of apoptosis is not sufficient to phenocopy the aggressive tumor progression associated with complete loss of p53 activity. We conclude that apoptosis is the primary tumor suppressive p53 function and the ablation of additional p53 pleiotropic effects further exacerbates tumor progression.

Indexed as

AnimalsApoptosisbcl-2-Associated X ProteinBrain NeoplasmsCarcinomaCell Transformation, NeoplasticFemaleMaleMiceMice, KnockoutMutationNeoplasms, ExperimentalSelection, GeneticTumor Suppressor Protein p53bcl-2-Associated X ProteinTumor Suppressor Protein p53

Identifiers

PMID21385880
PMCPMC3078190
OpenAlexW2126668016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.